Jazz Pharmaceuticals to acquire Actio Biosciences in deal with $820 million initial value
Jazz subsidiary Jazz Pharmaceuticals, Inc. agreed on August 10, 2026 to acquire Actio Biosciences, Inc. through a merger, with Actio becoming a wholly owned subsidiary. The upfront value starts at an initial $820 million, adjusted for items such as cash, debt and unpaid expenses, and holders may also receive up to $500 million in milestone payments tied to ABS-1230. Completion depends on conditions including HSR antitrust clearance, approval by holders of at least 85% of Actio's shares, and a spin-out of non-ABS-1230 programs.
Key points
- Initial aggregate upfront value of $820 million, subject to cash, debt, unpaid expense and tax adjustments
- Up to $500 million in milestones: $250 million on regulatory approval for KCNT1-Related Epilepsy, $100 million at $500 million annual net sales, and $150 million at $1 billion annual net sales
- Closing requires completion of a spin-out of non-ABS-1230 programs into a new company in which Parent takes a minority stake
- If the merger has not closed by an End Date five months after signing, either party may terminate; the agreement contains no termination fees
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.